IMPORTANT NOTICE
After careful consideration, we have decided to postpone ACI’s Biosimilars & Innovator Biologics in order to do our part to ensure the safety of our attendees, speakers, exhibitors, and staff.
Originally scheduled for June 24 – 25, 2020, Biosimilars & Innovator Biologics will now take place on September 23 – 24, 2020 in Boston.
We apologize for the inconvenience and will update this page very soon. Please check back shortly. We look forward to seeing you in September.
As we prepare to enter the next decade of this revolutionary law, we cordially invite you to join us for ACI’s 11th Annual Biosimilars & Innovator Biologics Summit.
As the number of FDA-approved biosimilar products continues to grow, the need for a solid guiding framework becomes more critical than ever before. While the stakeholders wait for finality on the rules governing significant matters like interchangeability, substitution and equivalency, it is clear that biosimilars will remain a top priority for the FDA.
The biosimilars market continues to maintain momentum as we head into 2020, but questions remain as to whether the U.S. market will catch up with Europe and whether biosimilars will provide their intended cost-savings.
Join the “who’s who” of the biosimilars and innovator biologics industries as they gather in Boston for ACI’s 2020 Summit on Biosimilars & Innovator Biologics, and contemplate these and other probing questions.
2020 Top Features
FDA KEYNOTE: Biosimilars and Interchangeable Products: FDA Perspective
PTAB: The APJs Speak on Practice, Policy and Procedure
View from the Bench: Pleadings, Motions, Discovery and Resolving Cases Through Settlement
In-House Town Hall: An Insider’s Guide to What In-House Counsel Expect from Law Firm Counterparts
FTC KEYNOTE: Antitrust Developments Impacting Biosimilars and Innovators
Sign up and stay tuned for more exciting programming announcement and our incredible speaker line-up!
Keep Me NotifiedWho You Will Meet
In-house counsel from branded and biosimilars companies
Government representatives from the FDA, USPTO, and the Judiciary
Leading regulatory and patent attorneys from around the country
Don’t miss this opportunity to benchmark your biosimilar strategies
with top industry representatives.
Register now and enjoy early bird savings!
Register NowThank You to Our Esteemed 2019 Biosimilars Co-Chairs
Immac “Casey” Thampoe
Executive Director/Assistant General Counsel
IP Portfolio Development
Regeneron Pharmaceuticals, Inc.
Year after year, the ACI Biosimilar Conference has featured a top-notch faculty from the pharma/biotech industry, private practice and government to address hot-button issues in this rapidly evolving area — I am looking forward to another outstanding event.
Charles K. Sholtz
Director and Associate General Counsel
Biosimilars, Manufacturing & Litigation Readiness Lead
Genentech
If I had to pick only one event to get the latest on issues impacting biosimilars, it would be the ACI Biosimilar Conference — highly informative presentations and ample opportunities to network and catch-up with players in this space.
Sample Past In-House Attendance
- Acceleron Pharma Inc
- Aceto Corporation
- Acorda Therapeutics Inc
- Actavis Generics
- ALDER BIOPHARMACEUTICALS
- Alexion Pharmaceuticals Inc
- Allergan
- Amgen
- AMRI Inc
- Apotex Corporation
- Association for Accessible
- Medicines
- Athersys Inc
- Baker Bros. Advisors LP
- Barr Laboratories
- Bausch & Lomb Inc
- Baxter Healthcare Corp
- Bayer HealthCare LLC
- Bedford Laboratories
- Ben Venue Laboratories
- Biogen
- BioMarin Pharmaceutical Inc.
- Boehringer Ingelheim GmbH
- Brattle Group
- BRM Biopharm Source LLC
- Celgene Corporation
- Centocor Inc
- Cerulean Pharma Inc
- Chemo Espana
- ChemWerth Inc
- Coherus Biosciences Inc
- Cornerstone Research
- Daiichi Sankyo Co Ltd
- DaVinci Healthcare
- Dr. Reddy’s Laboratories
- Duke University Fuqua School of
- Business
- Eisai Co Ltd
- Elan Pharmaceuticals Inc
- Eli Lilly & Company
- EMD Serono Inc
- Endo Pharmaceuticals Inc
- Ernest Mario School of Pharmacy
- Fresenius Kabi Deutschland GmbH
- Gedeon Richter Pharma GmbH
- Gene Techno Science Co Ltd
- Genentech
- Genzyme
- Gilead Sciences
- Glaxosmithkline Plc
- Glycobia
- GSK
- GTC Biotherapeutics Inc
- Hoffmann-La Roche
- Hospira Inc
- ImClone Systems Incorporated
- Immunogen Inc
- Johnson & Johnson
- LG Life Sciences
- Lonza
- Lupin Pharmaceuticals Inc
- Medicago Inc
- Medicines Company
- MedImmune Inc AstraZeneca
- Merck & Co
- Millennium Pharmaceuticals Inc
- Momenta Pharmaceuticals Inc
- Mylan
- National Institute of Allergy &
- Infectious Diseases
- Navigators Insurance
- Neose Technologies Inc
- Novartis Oncology
- Novo Nordisk
- Paravid LLC
- PDL Biopharma Inc
- Pfizer Inc
- PhRMA
- Purdue Pharma LP
- R-T Specialty LLC
- Regeneron Pharmaceuticals Inc
- Roche Inc
- Samsung Bioepis Co Ltd
- Sanofi
- Seattle Genetics Inc.
- Shionogi & Co Ltd
- Shire Pharmaceuticals
- Sunovion Pharmaceuticals Inc
- Sutro Biopharma Inc
- Takeda Pharmaceuticals
- Teva Pharmaceutical
- UCB Inc
- Vertical Pharmaceuticals Inc
- Wyeth BioPharma
- Zydus Research Centre
Can’t Join Us in Person?
Register for the livestream format and attend the conference from the comfort of your workplace or home.
Learn More
ACI’s Global Series of Life Sciences Conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy. Learn More
